Lantheus Holdings Inc
NASDAQ:LNTH

Watchlist Manager
Lantheus Holdings Inc Logo
Lantheus Holdings Inc
NASDAQ:LNTH
Watchlist
Price: 90.52 USD 3.66% Market Closed
Market Cap: 6.3B USD
Have any thoughts about
Lantheus Holdings Inc?
Write Note

Net Margin
Lantheus Holdings Inc

28.6%
Current
9%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
28.6%
=
Net Income
427.6m
/
Revenue
1.5B

Net Margin Across Competitors

Country US
Market Cap 6.3B USD
Net Margin
29%
Country JP
Market Cap 6.8T JPY
Net Margin
24%
Country CH
Market Cap 37.9B CHF
Net Margin
12%
Country DK
Market Cap 200.9B DKK
Net Margin
19%
Country US
Market Cap 16.9B USD
Net Margin
11%
Country KR
Market Cap 9.9T KRW
Net Margin
-358%
Country CA
Market Cap 6.9B USD
Net Margin
-8%
Country CN
Market Cap 48.6B CNY
Net Margin
42%
Country US
Market Cap 6.1B USD
Net Margin
9%
Country UK
Market Cap 4.8B GBP
Net Margin
7%
Country CH
Market Cap 4.9B CHF
Net Margin
12%
No Stocks Found

Lantheus Holdings Inc
Glance View

Market Cap
6.3B USD
Industry
Health Care

Lantheus Holdings Inc. is a dynamic healthcare company specializing in the development, manufacture, and commercialization of innovative diagnostic imaging agents, particularly in the field of nuclear medicine. Founded in 1956, the company has established a solid reputation for improving patient care through advanced diagnostics, helping healthcare providers make more informed decisions. Lantheus is perhaps best known for its flagship products, including nuclear imaging agents like Pylarify, used in the detection of prostate cancer. With a robust pipeline of novel radiopharmaceuticals in various stages of development, the company is strategically positioned to address unmet needs in diagnostics and therapeutics, thereby enhancing both patient outcomes and shareholder value. For investors, Lantheus represents a compelling opportunity, particularly as the demand for precision medicine continues to grow. With healthcare trends increasingly leaning towards personalized treatment, Lantheus is poised to grow through strategic partnerships, expanding market access, and leveraging new technologies. The company's commitment to innovation is underscored by its recent achievements and promising clinical trials, which have the potential to reshape the landscape of cancer diagnostics and treatment. As Lantheus Holdings continues to expand its portfolio and strengthen its market presence, investors can look forward to both solid financial performance and meaningful contributions to the evolving field of medical diagnostics.

LNTH Intrinsic Value
147.73 USD
Undervaluation 39%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
28.6%
=
Net Income
427.6m
/
Revenue
1.5B
What is the Net Margin of Lantheus Holdings Inc?

Based on Lantheus Holdings Inc's most recent financial statements, the company has Net Margin of 28.6%.